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mTOR kinase is one of the basic links at the crossroad of several signal transduction pathways. De re gulated 
mTOR kinase signaling accompanies the progress of cancer, diabetes, neurodegenerative disorders and ag-
ing. Implication of mTOR inhibitor rapamycin decreases migration and invasion of malignant cells, and 
metastasis formation. However, a precise mechanism of the regulation of cellular locomotion by mTOR 
kinase is not fully understood. This article focuses on the recent fi ndings that demonstrated a possible role 
of mTOR kinase in the regulation of cytoskeleton remodeling and cell migration properties. Detailed studies 
on this non-canonical mTOR function will extend our knowledge about cell migration and metastasis for-
mation and might improve anti-cancer therapeutic approaches.
K e y w o r d s: mTOR signaling, rapamycin, cytoskeleton remodeling, intermediate fi laments, microtu-
bules, cancer metastasis.
Introduction
The mTOR (mammalian target of rapamycin) kinase 
is a central link of several signaling pathways that 
integrates the signals from growth factors, hor mones, 
stress, energy status, and amino acids to con trol the 
organism growth, homeostasis and aging. mTOR acts 
through two functionally and struc turally distinct 
complexes, named mTORC1 and mTORC2 (mTOR 
complex 1 and 2). 
Taken together, active mTOR complexes stimu-
late the cellular growth and proliferation by positive 
regulation of transcription, translation, riboso me bio-
genesis, cell survival, inhibition of autopha gy and 
apoptosis [1]. Overactivation of the mTOR kinase 
was found in a range of human diseases, such as dif-
ferent types of cancer, type 2 diabetes, obesity, and 
neurodegenerative disorders. The re fore, mTOR is con-
sidered as a perspective target of anti-cancer and an-
ti-aging therapies [2].
One of the most dangerous stages of oncogenesis 
is the metastasis formation. At this stage the tumor is 
considered malignant. It is known, that the primary 
tumor causes death only in 10 % of the patients, whe-
reas 90 % of deaths are caused by metastases [3]. 
The metastasis formation is directly dependent on 
the cell motility and invasion, which allow the cells 
to change a position within the tissues. It was shown, 
that known mTOR inhibitor rapamycin and its syn-
thetic analogs can demonstrate not only cytostatic 
effects, but a decrease in the motility of cancer cells 
as well [4, 5]. However, the mechanism of the regu-
lation of cell migration and invasion by mTOR ki-
nase is not fully understood. 
The cytoskeleton, a cytoplasmic system of fi bers, 
is critical to sustain cell motility. Intermediate fi la-
ments, actin-containing microfi laments and microtu-
bules are the three main cytoskeletal systems of ver-
tebrate and many invertebrate cells. The rearrange-
ments of the cytoskeleton architecture are the main 
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reason of the cell locomotion [6]. Early studies re-
vealed that mTORC2 regulates the actin cytoskele-
ton polarization in yeasts. Moreover, further research 
showed that inactivation of both mTOR complexes 
impairs the movement of normal and cancer cells 
[7]. This article focuses on the recent studies reveal-
ing the role of mTOR kinase in the cytoskeleton re-
modeling and cell locomotion. 
Structure and functions
of mTOR kinase complexes
TOR (Target of Rapamycin) is a serine/threonine 
protein kinase, the activity of which is inhibited 
specifi cally by macrolide rapamycin (the other na-
me sirolimus). Rapamycin, produced by fi lamentous 
bacterium Streptomyces hygroscopicus, was ini-
tially found in the soil sample of the Easter Island 
(Rapa Nui) in 1970s and subsequently discovered to 
have antifungal, immunosuppressive and cytostatic 
effects. Biochemical studies and genetic scree ning 
in the yeast mutants, resistant to the growth-inhibi-
tory properties of rapamycin, led to the identifi ca-
tion of TOR kinase [8]. Interestingly, rapamycin 
does not directly inhibit TOR, but it forms a com-
plex with cytosolic protein FKBP12 (FK506 bind-
ing protein 12 kDa, the other name FKBP1A). The 
rapamycin-FKBP12 complex binds to the C termi-
nal part of TOR molecule, termed FRB (FKBP12-
rapamycin binding domain), thereby in hibiting TOR 
kinase activity and functions [9]. Further studies re-
vealed the homologues of yeast TOR in the fl ies 
(Drosophila me lanogaster), worms (Caenorhabditis 
elegans), fun gus Cryptococcus neoformans, plants 
(Arabi dop sis tha liana) and mammals. That indi-
cates a high evolutionary conservatism of the ki-
nase, and hence its im por tant role in the regulation 
of intracellular processes. 
It should be noted that although mTOR originally 
stood for ‘mammalian TOR’, it is now also used of-
fi cially as an abbreviation for ‘mechanistic TOR’. Un-
fortunately, sometimes the expression ‘me cha nistic 
TOR’ is used to indicate TOR kinase from any spe-
cies that brings some confusion in the fi eld [10]. To 
prevent further confusion we will use the term mTOR 
when discussing kinase in mammalian organisms.
In mammalian cells mTOR is a catalytic compo und 
of two different complexes mTORC1 and mTORC2, 
which coordinates anabolic and catabolic processes 
in response to growth factors and nutrients. The mTOR-
containing complexes have different sensitivities to 
rapamycin as well as upstream regulators and down-
stream targets.
Components and substrates of mTOR complex 1
The most studied complex is mTORC1. It consists 
of mTOR, Raptor (regulatory-associated protein of 
mTOR), mLST8 (mammalian lethal Sec13 protein 
8), PRAS40 (proline-rich kt substrate 40 kDa), Dep-
tor (DEP-domain-containing mTOR-interacting pro-
tein), and the Tti1/Tel2 complex. Raptor and PRAS40 
are unique components of mTORC1. The known fun-
ctions of mTOR partner proteins are listed in the Tab-
le 1 [11]. Cryo-electron studies revealed that mTORC1 
is an obligate dimer with an overall rhomboid shape 
and a central cavity. It was shown that the dimeric 
interfaces were formed by interlocking interactions 
between the mTOR and Raptor subunits. It was also 
proposed that some mTORC1 substrates with multi-
ple phosphorylation sites could shuttle between the 
two mTOR active sites within the dimer [12].
mTORC1 acts as a signal integrator for four major 
regulatory inputs: nutrients, growth factors, energy 
and stress. Growth factors and hormones regulate 
mTORC1 through several different signaling path-
ways, such as PI3K/Akt network, Ras–Raf–MAPK/
Erk signaling and Wnt pathway. The implication of 
multiple growth factor-initiated pathways in mTORC1 
regulation is likely to allow mTOR to participate in 
many developmental and physiological processes [1].
The most studied upstream regulators of mTORC1 
are the elements of PI3K/Akt/mTOR signaling net-
work: PI3K (phosphatidylinositol-3-kinase), Akt (the 
other name PKB, protein kinase B), TSC1–TSC2 
(tu berous sclerosis complex 1 and 2) and small GTPase 
RHEB (Ras homolog enriched in brain). Binding 
growth factors to the receptor tyrosine kinases initi-
ates the production of the second messenger PIP3 
(phosphatidylinositol 3,4,5 triphosphate) by PI3K. 
This lipid serves as plasma membrane docking site 
for Akt. Recruiting Akt to the membrane induces its 
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phosphorylation and activation. In turn, activated 
Akt phosphorylates TSC2 (also known as tuberin), a 
large protein that, together with TSC1 (also known 
as hamartin), forms the TSC1–TSC2 complex. TSC1–
TSC2 acts as a GTPase activating protein (GAP) for 
RHEB and promotes its loading with GDP. Akt-
mediated phosphorylation of TSC2 inhibits GAP ac-
tivity of the TSC1–TSC2 complex and induces 
RHEB to bind GTP. The GTP-bound form of Rheb 
directly interacts with mTORC1 and strongly stimu-
lates its kinase activity [13, 14].
Nutrients activate mTORC1 through amino acids 
availability. Import of the amino acids causes small 
Rag GTPases to switch to the active conformation. 
The active Rag heterodimer physically interacts with 
Raptor, causing mTORC1 to cluster onto the surface 
of late endosomes and lysosomes, where the Rag 
GTPases reside. This relocalization enables mTORC1 
to interact with its activator RHEB [15, 16].
In mammalian cells the most extensively studied 
substrates of mTORC1 are S6Ks (ribosomal protein 
S6 kinases) and 4E-BP1 (eIF4E- binding protein 1). 
The main function of these proteins is the regulation 
of mRNA translation initiation and progression, thus 
controlling the rate of protein synthesis. Previous 
studies have shown that both proteins contain TOS 
(TOR signaling) motifs. Mu tations in the amino acid 
sequence of the TOS motif signifi cantly reduces the 
level of phosphorylation of S6K and 4E-BP1 under 
in vitro conditions, due to the impaired ability of 
these proteins to interact with Raptor. Besides the 
canonical function of the mentioned mTOR targets, 
they are involved in the regulation of cell viability, 
migration, cytoskeleton remodeling etc. [17–19].
Components and substrates
of mTOR complex 2
Com pared to mTORC1, less is known about mTORC2. 
It is insensitive to amino acids, but responds to growth 
factors through a poorly defi ned mechanism.
mTORC2 is formed by mTOR, Rictor (rapa my-
cin-insensitive companion of mTOR), mLST8, Dep-
tor, mSIN1 (mammalian stress-activated pro tein ki-
nase interacting protein) and Protor-1 (pro tein ob-
served with Rictor-1, also known as PRR5). Ric tor, 
mSin1 and Protor-1 are unique components of 
mTORC2. The known functions of mTORC2 pro-
teins are listed in the Table 1. In yeasts, TORC2 is 
Table 1. The known functions of mTORC1 and mTORC2 proteins
mTOR Serine/threonine kinase, catalytic subunit of the complex
mTORC1
Raptor Scaffold protein, regulates the assembly, substrates binding and localization of mTORC1. Unique 
component of mTOR complex 1.
PRAS40 mTOR inhibitor. Unique component of mTORC 1.
Deptor mTOR inhibitor
mLST8 Unknown function. The loss of mLST8 does not affect mTORC1 activity towards its substrates
Tti1/Tel2 complex Scaffold proteins, which regulate mTORC1 assembly and stability
mTORC2
mTOR Serine/threonine kinase, catalytic subunit of the complex
Rictor Scaffold protein, regulates the assembly and substrates binding of mTORC2. Unique component of 
mTOR complex 2.
mSin1 Scaffold protein regulating the assembly, stability of mTORC2 and its interaction with SGK1. Unique 
component of mTOR complex 2.
Protor-1 Increases mTORC2-mediated activation of SGK1. Unique component of mTOR complex 2.
Deptor mTOR inhibitor
mLST8 Unknown function. The loss of mLST8 does not affect mTORC1 activity towards its substrates
Tti1/Tel2 complex Scaffold proteins, which regulate mTORC1 assembly and stability
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oligomeric and forms homodimers, but whether 
mTORC2 can form dimers/multimers in ma m ma lian 
cells is unknown. mTORC2 is insensitive to acute 
rapamycin treatment. However, chro nic treat ment 
with rapamycin inhibits mTORC2 functions in many 
cell lines, possibly, by sequestration of all mTOR 
molecules and, therefore, prevention of the de novo 
mTORC2 assembly [20]. 
It was revealed, that mTORC2 substrates are the 
AGC kinase family members, such as: Akt, cPKCs 
(conventional protein kinases C) and SGK (serum- 
and glucocorticoid-regulated kinase). Thro ugh these 
kinases mTORC2 takes part in the regulation of cell 
survival, cell cycle progression and anabolism [1, 20]. 
Participation of mTOR kinase in the regulation
of cytoskeleton reorganization
The initial characterization of mTORC2 led to the 
discovery of the participation of mTOR signaling in 
actin cytoskeleton polarization and cell movements 
[21]. Recent studies revealed that both complexes: 
mTORC1 and mTORC2 play a crucial role in the 
processes of cell motility and invasion through regu-
lation of cytoskeleton remodeling [22].
Interplay between mTOR kinase
and intermediate fi laments
Intermediate fi laments (IFs) form an extensive cy-
toskeletal network within the cell (Fig. 1, A).
The subunits composing intermediate fi laments 
constitute a superfamily of α-helical proteins that are 
found in the cytoplasm of different tissues and on the 
nuclear membrane. In humans, there are at least 67 
genes that encode IF proteins, which ma kes this gene 
family one of the largest in the human genome. The 
various members of the intermediate fi lament pro-
tein family are expressed differentially in complex 
patterns during embryonic development and in the 
terminally differentiated tissues. So, this superfamily 
has been divided into fi ve distinct types on the basis 
of similarities in sequence and their patterns of ex-
pression in cells (Table 2) [6, 23, 24].
Phosphorylation rate plays an important role in 
the assembly and disassembly of the intermediate 
fi laments. Hyperphosphorylation of multiple sites of 
the IFs during mitosis causes rapid disassembly of 
the fi laments and their separation to the daughter 
cells. Recent studies also showed high level of fl ex-
ibility of the IFs even in stationary interphase cells. 
These fi ndings suggest that dynamic of IF cytoskel-
eton remodeling is under the control of kinases and 
phosphatases [23, 25].
For a long time, IFs have been considered as com-
ponents of the cell that maintain the cellular shape 
and provide resistance to mechanical stress. However, 
a lot of recent studies revealed novel non-canonical 
functions of intermediate fi lament proteins. For ex-
ample, it was shown that keratins mediate localiza-
tion of the hemidesmosomes and desmosomes in the 
human keratinocytes. Dep le tion of all keratins by 
genome engineering caused altered distribution of 
the hemidesmosomal proteins, which resulted in a 
faster adhesion and migration of keratin-free cells 
[26]. Moreover, analyses of vimentin −/− mice have 
revealed that loss of vimentin leads to impaired 
wound healing due to defects in the capacity of fi -
broblasts to migrate [27]. These fi ndings support a 
hypothesis that intermediate fi laments play impor-
tant role in cell motility and that altered regulation of 
Table 2. Classifi cation of the intermediate fi laments
Type
of IFs IFprotein Tissue distribution
Type I Acidic keratins All types of the epithe-
liaType II Basic keratins
Type III Vimentin 
Desmin 
Glial fi brillary acidic 
protein
Peripherin
Mesenchymal cells
Muscle
Glial cells, astrocytes
Neurons
Type IV NF(Neurofi laments)-L 
NF-M 
NF-H
Nestin
Internexin
Syncolin
Neurons
Neurons
Neurons 
Neuroepithelial stem 
cells
Neurons
Muscle cells
Type V Lamins A, C, B1, B2 Nuclear lamina of all 
types of the cells
Beaded
fi laments
Phakinin
Filensin
Intermediate fi laments 
of the ocular lens
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IFs assembly could be involved in cancer cell spread-
ing. Also, intermediate fi laments take part in the 
apoptosis regulation and cell signaling. 
Studies on the keratin 17 (K17)-null mouse skin 
keratinocytes revealed that K17 regulates cell growth 
and size through mTOR signaling. Keratin 17 is an 
intermediate filament protein rapidly induced in 
wounded stratified epithelia that alters cellular vis-
coelastic properties and optimizes tissue repair. Mo-
use skin keratinocytes lacking K17 show dep ressed 
protein translation and are of smaller size, correlat-
ing with decreased Akt/mTOR signaling activity. It 
was discovered that K17 regulates mTOR activation 
through binding to the adaptor protein 14-3-3σ. Two 
amino acid residues located in the amino-terminal 
head domain of keratin 17 are required for the se-
rum-dependent relocalization of 14-3-3σ from the 
nucleus to the cytoplasm, and for the sti mulation of 
mTOR activity and cell growth [28].
Another evidence of the cooperation between IFs 
and mTOR kinase comes from the research of the 
transgenic mice lacking the entire keratin multipro-
tein family. All keratin-null embryos die from severe 
growth retardation at embryonic day 9.5. Em bryonic 
epithelia suffer no cytolysis but display mislocalized 
desmo- somes and glucose transporters GLUT1 and 
GLUT3. An altered localization of glucose trans-
porters subsequently activates the energy sensor ad-
enosine monophosphate kinase (AMPK). AMPK is 
a negative mTORC1 regulator, it inactivates mTOR 
signaling, thereby represses protein biosynthesis in 
keratin-null embryos [29].
Treatment of a human HaCaT keratinocyte cell 
line with mTOR inhibitors (rapamycin, temsirolimus 
or everolimus) resulted in selective keratin 6a (K6a) 
repression. Furthermore, treatment of the HaCaT 
cell line with the siRNAs targeting components of 
the mTOR pathway altered the levels of K6a expres-
sion. Oral rapamycin administration also improves 
the symptoms in pachyonychia congenita patients, 
suggesting mTOR inhibitors may be a therapeutic 
option for people with mutations that disrupt the in-
termediate fi laments formation. The se results show a 
possible bidirectional interplay between mTOR ki-
nase and intermediate fi lament proteins [30]. 
It is known that the site-specifi c phosphorylation 
of IF proteins induces the disassembly of the fi la-
ment structures. During mitosis, the hyperphos pho-
rylation of intermediate fi laments by Cdk1 (Cyc lin-
dependent kinase 1), Plk1 (Polo-like kinase 1), Rho- 
and Aurora-B kinases is essential for the effi cient 
segregation of IF networks into daughter cells [31]. 
However, it was revealed that IF network is also a 
highly mobile structure in the interphase cells and its 
remodeling is under the control of protein kinases 
and phosphatases, such as protein kinase C (PKC) 
and protein kinase A (PKA) [25].
Regulation of actin cytoskeleton
reorganization by mTOR kinase
A globular protein actin forms microfi laments, which 
are 7 nm in diameter polar fi brils that organize an 
extensive network in the cytoplasm of all eukaryotic 
cells (Fig. 1, B). Actin can be present as either a free 
monomer G-actin (globular) or a part of a linear 
polymer microfi lament called F-actin (fi lamentous). 
All actin subunits in the microfi lament point toward 
the same end of the fi lament. Actin fi lament exhibits 
polarity: the end that possesses an actin subunit that 
has its ATP binding site exposed is called the «(-) 
end», whereas the opposite end where the cleft is di-
rected at a different adjacent monomer is called the 
«(+) end». The assembly of G-actin into F-actin is 
accompanied by the hydrolysis of ATP. Actin par-
ticipates in many important cellular processes, in-
cluding muscle contraction, cell motility, cell divi-
sion, vesicle and organelle traffi c, and the establish-
ment and maintenance of cell junctions [6, 32].
Early studies on TOR kinase revealed that deletion 
of TOR2 disrupted the polarized organization of the 
actin cytoskeleton in yeasts. In mammalian cells 
mTORC2 also seems to regulate the remodulation of 
actin cytoskeleton [21]. Knockdown of mTOR, Ric tor 
or mLST8 in the serum-starved NIH 3T3 fi broblast 
cells resulted in the defective F-actin fi bres formation 
in response to serum, whereas knockdown of raptor 
did not affect actin polymerization and cell spreading. 
Additionally, disruption of mTORC2 reduced phos-
phorylation of the focal adhesion proteins, as well as 
F-actin reorganization and cell motility [33, 34]
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The actin cytoskeletal rearrangements are regu-
lated by intracellular signaling pathways directed by 
Rac (Ras-related C3 botulinum toxin substrate), Rho 
(Ras homolog gene family), and Cdc42 (Cell divi-
sion control protein 42 homolog), all Ras-like mol-
ecules belonging to the GTPase superfamily of 
switch proteins [6]. So, it was interesting whether 
mTOR could infl uence actin cytoskeleton architec-
ture through these proteins. Indeed, further research 
showed that in yeasts TOR2 activated Rho1 and 
Rho2 via their exchange factor ROM2 (Rho1 gua-
nine nucleotide exchange factor 1). However, the 
actual mechanism by which TORC2 regulates the 
Rho1 GTPase pathway is not well studied [35, 36].
Depletion of mTOR and Rictor, but not Raptor, 
impairs actin polymerization, leading edge estab-
lishment, and directional migration in neutrophils 
stimulated with chemoattractants. It was shown that 
depletion of Rictor inhibits Rac and Cdc42 activi-
ties, supposing that they are the target of mTORC2. 
Interestingly, depletion of mSin1, an integral com-
ponent of mTORC2, caused no detectable changes 
in neutrophil polarity and chemotaxis [37, 38].
Several recent studies pointed to the mTORC2 in-
volvement in the formation of long-term memory by 
regulating and stabilizing the actin cytoskeleton in 
the dendritic spines of neurons. Rictor-defi cient mice 
showed a reduction in the ratio of fi brilar actin 
(F-actin) to actin monomers, as well as a reduction in 
the expression of a number of upstream positive reg-
ulators of actin polymerization. These data suggested 
that mTORC2 is required for the long-term memory 
formation by increasing the F-actin important for 
dendritic spine growth and remodeling [39, 40].
Fig. 1. The architecture of different types of the cytoskeleton fi bers in the human breast adenocarcinoma MCF-7 cell line: intermedi-
ate fi laments (A), microfi laments (B), microtubules (C)
Fig. 2. Immunofl uorescent analysis of the phospho-mTOR Ser2481 (B) colocalization with tubulin β (A) during cytokinesis in the 
human breast adenocarcinoma MCF-7 cell line. Nuclei were counterstained with Hoechst 33342 (C)
A B C
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Merge
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Current research revealed that mTORC1 also could 
be implicated in the actin cytoskeleton reassembly in 
different cells. It was shown that rapamycin treat-
ment induced S6K inactivation, inhibited actin stress 
fi ber formation and cell migration in a wide range of 
mammalian cell lines. Further studies discovered that 
S6K, Akt, PDK1, and activated mTOR were localized 
to the actin arc of the Swiss 3T3 fi broblasts [10]. 
Rapamycin treatment blocked the epidermal growth 
factor (EGF)-induced actin arc formation in these cells, 
supporting a hypothesis, that mTORC1/S6K axis is 
also important for the cytoskeleton regulation [41]. It 
was observed that rapamycin inhibited IGF-I-induced 
F-actin reorganization and phosphorylation of the focal 
adhesion proteins, such as FAK (Focal adhesion ki-
nase), paxillin and p130Cas, by inhibition of the S6K1 
activity [7, 33]. Knockdown of mTORC1 and mTORC2 
induced a mesenchymal-epithelial transition in the col-
orectal cancer cells, due to increased cell-cell contacts 
as well as decreased actin cytoskeletal remodeling and 
decreased activation of the small GTPases, RhoA and 
Rac1 [36]. It supports the idea that mTOR could regu-
late cytoskeleton rearrangement through phosphoryla-
tion of the actin-remodulating proteins. 
The present study showed that activated PI3K-Akt-
mTOR signaling pathway promotes invasion and me-
tastasis in hepatocellular carcinoma though up-regu-
lation of MMP-9 (Matrix metalloproteinase 9), tho-
ugh, indicating that mTORC1 could infl uence cellular 
locomotion by several distinct directions [42, 43].
The crosstalk between mTOR kinase
and microtubules
A microtubule is a polymer of globular tubulin sub-
units, which are arranged in a cylindrical tube mea-
suring 25 nm in diameter – the thickest fi brils of the 
cytoskeleton (Fig. 1, C). Similar to F-actin a micro-
tubule is polarized and has (+) end and (-) end. Po ly-
merization of the tubulin subunits requires the hy-
drolysis of the GTP molecules. In addition to regula-
tion of the cell motility, microtubules play a major 
role in organization of the cell polarity through a spe-
cial structure called the microtubule-organizing cen-
ter (MTOC). Loca ted near the nucleus, the MTOC 
directs the assembly and orientation of microtubules, 
the ro u te of vesicle tra ffi cking, and the orientation of 
organelles. Mic ro tubules play a crucial role during 
mitosis by the formation of mitotic spindle, which is 
used to separate eukaryotic chromoso mes. A large 
number of proteins infl uences the assembly and sta-
bility of microtubules and their association with oth-
er cell structures. These proteins are collectively cal-
led microtubule-associated prote ins (MAPs) [6, 32].
Involvement of TOR1 and TOR2 in the control of 
various aspects of microtubule dynamics was report-
ed in yeasts [44]. However, the role of TORs in the 
regulation of microtubule dynamics has not been 
fully elucidated yet.
In mammalian cells mTOR was found to bind di-
rectly to and phosphorylate cytoplasmic linker pro-
tein of 170 kDa (CLIP-170), which is a MAP that 
binds to the (+) end of the microtubule and stabilizes 
it [45]. However, the exact function of this phospho-
rylation is not fully understood. It was revealed that 
TSC2 knockout resulted in a greater abundance of 
stabilized microtubules underneath the cellular cor-
tex. Time-lapse imaging of dynamic microtubules 
al so revealed disorganized movements of the grow-
ing microtubule plus-ends in the cellular cortex re-
gion, including growth in a direction that is parallel 
to the cortex. The authors suggested that the func-
tional mTOR-CLIP-170 interaction helps microtu-
bules grow to the cellular cortex [46].
It was shown that mTOR kinase is also involved 
in the regulation of intracellular transport associated 
with microtubules. Inhibition of the expression of 
TSC2, which is involved in the activation of mTOR, 
leads to disruption of the caveolin (scaffold protein, 
involved in the endocytosis) transport to the plasma 
membrane. Instead, it was detected in the vesicles, 
randomly located in the cytoplasm. Incubation of rat 
fi broblasts in the media that contain high concentra-
tions of mTOR inhibitor rapamycin led to the same 
result, and chaotic arrangement of microtubules in 
the cortical zone was observed in the cells [47]. 
Interestingly, mTORC1–tubulin relations were ob-
served to be bidirectional: the mTORC1 activation 
requires dynein-dependent transport to a position in 
the cell where it can be activated [48]. The associa-
tion between dynein and mTOR was shown by coim-
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munoprecipitation. Inhibition of dynein fun ction us-
ing RNAi hinders the mTORC1 activity in the hu-
man fi broblasts and the human glioblastoma–astro-
cytoma cell line U373-MG [48].
Moreover, the phosphorylated form of mTOR ki-
nase (phospho-mTOR Ser2481) was observed to lo-
calize at the cleavage furrow of different cell lines 
during cytokinesis. Inhibition of the polymerization 
of microtubules by nocodazole leads to the loss of 
phospho- mTOR (Ser2481) ability to target the spin-
dle midzone and the cleavage furrow during cytoki-
nesis. At these conditions phospho-mTOR was ran-
domly dispersed across the entire mitotic cytoplasm, 
indicating that mitotic traveling of phospho-mTOR 
(Ser2481) requires dynamic microtubules [49]. 
Using anti-phospho-mTOR (Ser2481) antibodies 
(Merck Millipore) we revealed the colocalization of 
phospho-mTOR (Ser2481) and tubulin β at the cleavage 
furrow that has not been demonstrated earlier (Fig. 2). 
Immunofl uorescent analysis was performed as de-
scribed [50]. Our fi ndings support a hypothesis that 
mTOR phosphorilated at Ser 2481 interacts with micro-
tubules during cytokinesis. However, further studies are 
needed to understand the mechanism of this process.
Conclusion
Novel fi ndings in the mTOR signaling fi eld shed light 
on the non-canonical functions of the mTOR kinase. 
The bidirectional crosstalk bet ween mTOR and all 
three types of the cytoskeleton points to the important 
role of mTOR signaling pathway in the normal cell lo-
comotion during embryonic development, wound heal-
ing, and che mo taxis as well as in the cancer cells 
spreading. Further detailed investigation of this new as-
pect of the mTOR activity might lead to the optimiza-
tion of the current anti-cancer therapeutic approaches.
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Характеристика mTOR
сигнального шляху та його залучення
до регуляції клітинної рухливості шляхом
реконструкції архітектури цитоскелету
mTOR кіназa є однією з основних ланок, розташованих на пе-
ретині кількох шляхів внутрішньоклітинної передачі сигналу. 
Дерегуляція сигналінгу mTOR кінази супроводжує розвиток 
онкологічних захворювань, діабету, нейродегенеративних роз-
ладів і старіння. Застосування інгібітора mTOR рапаміцина 
знижує рівень міграції та інвазії злоякісних клітин і утворення 
метастазів. Однак, точний механізм регуляції рухливості клі-
тин mTOR кіназою повністю не зрозумілий. Дана стаття при-
свячена останнім дослідженням, які демонструють можливу 
роль mTOR кінази в регуляції ре моделювання цитоскелету та 
міграції клітин. Докладні дослідження цієї неканонічної функ-
ції mTOR кінази дозволить розширити наші знання про мігра-
цію клітин і утворення метастазів і може привести до поліп-
шення протиракових терапевтичних підходів.
Ключов і  слова: mTOR сигналінг, рапаміцин, перебудова 
цитоскелету, проміжні філаменти, мікротрубочки, метаста-
зування.
В. Р. Косач, О. В. Чередник, А. И. Хоруженко
Характеристика mTOR сигнального пути
и его привлечения к регуляции клеточной подвижности
путем реконструкции архитектуры цитоскелета
mTOR киназa является одним из основных звеньев, располо-
женных на пересечении нескольких путей внутриклеточной пе-
редачи сигнала. Дерегуляция сигналинга mTOR киназы сопро-
вождает развитие онкологических заболеваний, диабета, нейро-
дегенеративных расстройств и старения. При менение ингиби-
тора mTOR рапамицина снижает уровень миграции и инвазии 
злокачественных клеток и образование метастазов. Однако, точ-
ный механизм регуляции подвижности клеток mTOR киназы 
полностью не изучен. Эта статья посвященна последним иссле-
дованиям, которые демонстрируют возможную роль mTOR ки-
назы в регуляции ремоделирования цитоскелета и миграции 
клеток. Под роб ные исследования этой неканонической функ-
ции mTOR киназы позволят расширить наши знания о мигра-
ции клеток и образование метастазов и может привести к улуч-
шению противораковых терапевтических подходов.
Ключевые  слова: mTOR сигналинг, рапамицин, пере-
стройка цитоскелета, промежуточные филаменты, микро-
трубочки, метастазирование.
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